Alkermes plc (ALKS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Blair C. Jackson
|
President, CEO & Director | 1.37M | -- | 1973 |
|
Mr. Joshua Reed M.B.A.
|
Senior VP & CFO | 743.97k | -- | 1973 |
|
Mr. David Joseph Gaffin J.D.
|
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 1.28M | -- | 1972 |
|
Dr. Craig C. Hopkinson M.D.
|
Executive VP of Research & Development and Chief Medical Officer | 1.42M | 4.51M | 1969 |
|
Mr. Christian Todd Nichols
|
Senior VP & Chief Commercial Officer | 1.06M | -- | 1970 |
|
Mr. Samuel J. Parisi
|
Interim Principal Accounting Officer & VP of Finance | -- | -- | 1975 |
|
Mr. Tom Skoff
|
SVP & Chief Information Officer | -- | -- | -- |
|
Ms. Sandra Coombs
|
Senior Vice President of Corporate Affairs & Investor Relations | -- | -- | -- |
|
Mr. Stephen Schiavo
|
Senior VP & Chief Human Resources Officer | -- | -- | -- |
|
Mr. Peter Norman
|
SVP of Policy, Government & Community Relations | -- | -- | -- |
Alkermes plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 2,050
Description
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Corporate Governance
Upcoming Events
November 3, 2026 at 1:30 PM UTC
Alkermes plc Earnings Date
